Inflammatory Bowel Disease Treatment Market Players:
- The Bristol-Myers Squibb Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bausch Health Companies Inc.
- AbbVie Inc.
- Novartis AG
- UCB Biopharma SRL
- Biogen Inc.
- Pfizer, Inc.
- Janssen Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Celltrion Healthcare Co., Ltd.
The market is evolving with the penetration of technological escalation and rigorous R&D cohorts. Key players in this sector are significantly contributing to this scenario by forming strategic partnerships, global-scale commercialization, and enhanced production. They are continuously developing innovative therapeutics to offer personalized care to every individual. For instance, in October 2023, Pfizer attained clearance from the FDA to market its oral, once-daily, receptor modulator, VELSIPITY (etrasimod). The recommended 2 mg dose of this medicine has been proven to be effective for treating adults with moderately to severely active ulcerative colitis. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of inflammatory bowel disease treatment is estimated at USD 26.13 billion.
The global inflammatory bowel disease treatment market size was more than USD 24.98 billion in 2025 and is anticipated to witness a CAGR of over 5.1%, crossing USD 41.08 billion revenue by 2035.
North America inflammatory bowel disease treatment market will dominate more than 57.8% share by 2035, driven by increasing IBD incidence and healthcare advancements.
Key players in the market include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited.
